AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01362530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Description: On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
Study NCT01362530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 80 mg
Description: On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
Study NCT01362530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant powder for suspension (PFS)
Description: On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to \<12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to \<12 years of age
Study NCT01362530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Day 1: Administered according to product label for pediatric usage or local standard of care
Study NCT01362530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: Day 1: Administered according to product label for pediatric usage or local standard of care
Study NCT04098601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Coach Intervention
Description: Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
Study NCT01385696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genuair® (Almirall S.A.)
Description: Inhaler with only placebo, once daily, 14 days
Study NCT01362530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Aprepitant 125 mg
Description: On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
Study NCT01362530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Aprepitant 80 mg
Description: On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
Study NCT01362530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Aprepitant PFS
Description: On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to \<12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to \<12 years of age
Study NCT01362530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emetogenic chemotherapy
Description: Any moderately or highly emetic chemotherapeutic agent such as cyclophosphamide, doxorubicin, methotrexate, carboplatin, cisplatin, irinotecan, carmustine, ifosfamide, and streptozocin, or chemotherapeutics of a lower emetogenicity that were not previously tolerated. No chemotherapeutic agents were specified by the protocol, and many could potentially have been used.
Study NCT01362530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Emetogenic chemotherapy
Description: Any moderately or highly emetic chemotherapeutic agent such as cyclophosphamide, doxorubicin, methotrexate, carboplatin, cisplatin, irinotecan, carmustine, ifosfamide, and streptozocin, or chemotherapeutics of a lower emetogenicity that were not previously tolerated. No chemotherapeutic agents were specified by the protocol, and many could potentially have been used.
Study NCT04314180 — intervention group
Intervention type: DEVICE
Intervention: Taking slit-lamp images
Description: The participant only needs to take several slit-lamp images as usual.
Study NCT01385696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HandiHaler® (Boehringer Ingelheim's)
Description: Inhaler with only placebo, once daily, 14 days
Study NCT00178412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Project for Hospitalized Elders & Family Caregivers
Description: Phase 1 in-hospital contact: Family caregivers complete baseline data, listen to a tape about helping the elderly relative cope with hospitalization, and work on a mutual agreement/identification of goals for participation in family member's hospital care (i.e., selection of two complications to focus on based on patient's illness condition)~Phase 2 pre-hospital discharge: Family caregivers listen to a second tape about coping with the hospital experience, participating in their family member's in-hospital care, and preparing for hospital discharge/transition to home
Study NCT00178412 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison Group
Description: Phase 1 in-hospital contact: Family caregivers complete baseline data and listen to an informational tape about hospital policies.~Phase 2 pre-hospital discharge: Family caregivers listen to a second informational tape about the hospital and medical center.
Study NCT01956643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gum chewing
Description: gum chewing
Study NCT01956643 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Routine care during NPO
Study NCT00932503 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl plus
Description: triclosan-coated polyglactin 910 suture materials with antiseptic activity (Vicryl plus®, Ethicon GmbH, Norderstedt, Germany)
Study NCT03390231 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator therapy
Description: It briefly cocultures the patient's lymphocytes with CB-SCs in vitro, induces immune tolerance through the action of autoimmune regulator (AIRE, expressed by CB-SCs), returns the educated autologous lymphocytes to the patient's circulation, and restores immune balance and homeostasis.
Study NCT05738512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medial Flap Coblation Turbinoplasty
Description: Reduction of the inferior turbinate to manage inferior turbinate hypertrophy
Study NCT01366014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: multiple dose, single schedule
Study NCT05738512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Submucous Resection
Description: Submucous Resection
Study NCT04792996 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention. case - control design.
Study NCT03533790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEP-Ru
Description: * Drug: ruxolitinib~* Drug: doxorubicin~* Drug: etoposide~* Drug: methylprednisolone
Study NCT01366014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral
Description: multiple dose, single schedule
Study NCT01366014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; oral
Description: matching placebo
Study NCT03976141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: mri
Description: knee mri
Study NCT02217982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simethicone
Study NCT02217982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide
Study NCT02217982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peanut Butter
Study NCT01204112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasocitinib (CP-690,550) plus Rifampin
Description: Period 1, Day 1: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 1-7: Rifampin 600 mg (single oral dose) q24h Period 2, Day 8: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 9: No treatment (discharge)
Study NCT01495546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early loading
Description: Patients stepping down immediately after THA
Study NCT01495546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late loading
Description: Patients stepping down after three weeks of HTA
Study NCT01133639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
Study NCT01133639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo plus standard of care
Study NCT03809572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: See Arm description
Study NCT01448551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Mobile Messages to Enhance Weight Loss for Teens
Description: For this trial adolescents will be allowed to use their own phone (with reimbursement for any study-related costs), or will be provided with a mobile phone, if requested. Participants will receive messages delivered daily over the course of 20 weeks. The content of the messages will be tailored on participants' responses to the MPOWER enrollment survey and the initial tailoring questionnaire. On school days, all messages will be sent after 3 pm (which is after school hours for most Michigan middle and high schools). Therefore, patients will not need to carry cell phones to school. The tailored messages will utilize various degrees of personalization, adaptation and feedback - including momentary assessments with feedback requiring a text reply from the adolescents.
Study NCT00693212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: Dosing was flexible and dependent on clinical judgement, AEs and treatment response.
Study NCT00693212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day
Study NCT00693212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Dosing is identical to the MPH arm except that the pills will contain no active medication.
Study NCT02602873 — intervention group
Intervention type: OTHER
Intervention: therapeutic drug monitoring
Description: with therapeutic drug monitoring , dose of tacrolimus can be adjusted by therapeutic drug monitoring.
Study NCT02044146 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ticagrelor, Prasugrel, Clopidogrel
Study NCT03548090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 90% body weight
Description: Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (90%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
Study NCT03548090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control 4-week exercise intervention
Description: This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The control group will perform three sets of ten repetitions of the following 4 exercises, for a total of 120 repetitions: 1) standing hip abduction against green theraband resistance with upper extremity support, 2) sit to stands from chair with no upper extremity support, 3) bilateral calf raises with upper extremity support, and 4) right and left weight shifting exercises using a wobble board with upper extremity support available if needed.
Study NCT03548090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 4-week exercise intervention
Description: This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The experimental group will perform the skateboard exercise with the optimal parameters established during studies 1 and 2 (that is, an incline angle of either 0 or 5 degrees and a body weight percentage of 50%, 75%, or 90%)--the forward and backward speed of the skateboard will be cued with a metronome that will set at a beats per minute that matches the foot strike cadence of someone walking at 0.7 m/s, and the magnitude of forward excursion of the skateboard will be individualized to the participant based on GAITRite® data (that is, step length of the non-paretic LE).
Study NCT03412630 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography Perfusion Imaging
Description: Undergo computed tomography perfusion imaging
Study NCT02261480 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: When possible, blood will be drawn as an extra aliquot utilizing the same needle stick procedure performed for standard of care.
Study NCT02261480 — intervention group
Intervention type: OTHER
Intervention: Nasopharyngeal wash
Description: Nasopharyngeal washes are optional for Group A and Group B participants. Nasopharyngeal washes will be performed on all subjects in Group C. The technique used will be the same as used for regular standard of care per St. Jude guidelines.
Study NCT02044146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor, Prasugrel, Clopidogrel
Study NCT03943667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m² in IV infusion over 30-40 minutes at Day 1, 8 and 15 followed by one week of rest.
Study NCT03943667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m² in IV infusion over 30-40 minutes at Day 1, 8 and 15 followed by one week of rest.
Study NCT03943667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m² in IV infusion over 60 minutes at Day 1, 8 and 15 followed by 1 week of rest.
Study NCT00381316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Technetium Tc99m Tetrofosmin injections
Description: Single Isotope: be 555 to 888 MBq (15 to 24 mCi) MYOVIEW at Rest/i.v./bolus.
Study NCT00381316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thallous Chloride T1-201
Description: Myoview SPECT Imaging
Study NCT02044146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor, Prasugrel, Clopidogrel
Study NCT00936039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: unloading
Description: 2 weeks of unloading of a single leg
Study NCT03837535 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Neuro, Lung/thorax, GI, Gynecologic, Urologic, Orthopedic, Vascular surgery
Study NCT00920270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebulized colistin
Description: nebulized colistin 75 mg every 12 hours
Study NCT00920270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antibiotics
Description: conventional parenteral antibiotics
Study NCT03704922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfusion
Description: Red cell units for transfusion
Study NCT02597361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Irbesartan: 150 or 300 mg o.d. The up-titration of irbesartan from 150 mg to 300 mg o.d. occur during the first 8 weeks following randomization
Study NCT02597361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo o.d. to match 150mg or 300mg irbesartan tablets
Study NCT00693108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone
Study NCT04629157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innova Lateral Flow Device
Description: The Innova Lateral Flow Device will be used on anterior nasal swab specimens and RT-PCR will be performed on nose and throat swabs.
Study NCT02526316 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: P16_37-63 peptide combined with Montanide® ISA-51 VG
Description: Patients will receive P16_37-63 peptide (100 µg) combined with Montanide® ISA-51 VG vaccination subcutaneously once a week for four weeks, followed by a 4 week rest period
Study NCT02526316 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: P16_37-63 peptide without Montanide® ISA-51 VG
Description: Patients will receive 30 mcg P16_37-63 peptide injected intradermally for test on delayed-type hypersensitivity (DTH) reactions.
Study NCT02533128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liberal blood pressure management
Description: Protocolized hemodynamic management to maintain mean arterial pressure (MAP) > 60 mmHg
Study NCT02533128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tight blood pressure management
Description: Protocolized hemodynamic management to maintain mean arterial pressure (MAP) > 75 mmHg
Study NCT03640988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dermaPACE
Description: Shockwave application
Study NCT03302936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine
Description: to be given preoperatively
Study NCT01900275 — intervention group
Intervention type: OTHER
Intervention: Urine collection
Description: Collection of 5 ml urine from urinary collection device (e.g. foley catheter).
Study NCT01726777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Normal cheddar cheese
Study NCT01726777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D3 supplemented cheddar cheese
Study NCT01319760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella 2.5 support
Description: Patients enrolled in the Impella arm will receive 24 hours of post-PCI hemodynamic support using the Impella 2.5
Study NCT01319760 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of care (Control)
Description: Standard care for STEMI patients post-PCI from ACC/AHA Guidelines
Study NCT01612793 — intervention group
Intervention type: DEVICE
Intervention: AlphaCore Device
Description: multiple stimulation treatments per day for duration of hospitalization
Study NCT03822403 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EQUIA
Description: Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
Study NCT03822403 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gradia Direct Posterior
Description: The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
Study NCT00909285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS stimulation
Description: TMS stimulation and cognitive training
Study NCT00909285 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Sham comparator
Study NCT00909285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: TMS stimulation and cognitive training
Study NCT00883194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRF-108
Description: Ropivacaine
Study NCT00883194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PRF-108 Placebo
Study NCT00883194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Solution
Study NCT00883194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRF-110
Study NCT04160403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy intervention
Description: NDT bases on neuroplasticity by which the brain change and reorganize itself and its processes according to practice and experience by a) facilitation of normal postural alignment and movement patterns; b) inhibition of the involvement during developmental and functional activities; and c) using sensory feedback (manual contact, visual integration, somatosensory reinforcement) for recovering function
Study NCT01378390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Expanded autologous adipose-derived adult stem cells (eASCs)
Description: Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into the fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure) at week 12 will receive a second dose of 40 million cells, using the same treatment approach.